September 2015

New Product - Spiriva Respimat

Spiriva Respimat (tiotropium (as tiotropium bromide monohydrate)) is indicated for the long‑term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (COPD), and for the prevention of COPD exacerbations. Spiriva Respimat is also indicated as add‑on maintenance bronchodilator treatment for asthma in adults currently treated with the maintenance combination of inhaled corticosteroids (≥ 800 microgram budesonide/day or equivalent) and long‑acting β₂ agonists and who experienced one or more severe exacerbations in the previous year. It is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, e.g. ipratropium or oxitropium. Spiriva Respimat is available as a solution for inhalation (cartridge) containing tiotropium 2.5 microgram (≡ tiotropium bromide monohydrate 3.1 microgram) + Respimat inhaler delivering 60 metered actuations.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au